News
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...
(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
20h
Pharmaceutical Technology on MSNEli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
"Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical ...
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...
3d
Zacks.com on MSNCan Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results